These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21913365)

  • 1. The political contradictions of incremental innovation: lessons from pharmaceutical patent examination in Brazil.
    Shadlen KC
    Polit Soc; 2011; 39(2):143-74. PubMed ID: 21913365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should ANVISA be permitted to reject pharmaceutical patent applications in Brazil?
    Mueller LL; Taketsuma Costa SM
    Expert Opin Ther Pat; 2014 Jan; 24(1):1-4. PubMed ID: 24206261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Brazil's pharma patent landscape.
    Gosain R
    Pharm Pat Anal; 2016 Sep; 5(6):385-390. PubMed ID: 27804784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding drug access in Brazil: lessons for Latin America and Canada.
    Cohen JC
    Can J Public Health; 2006; 97(6):I15-8. PubMed ID: 17203728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent developments in health law. India's evolving patent laws and WTO obligations: the rejection of Abbott Laboratories' application for a new Kaletra patent.
    Chilton A
    J Law Med Ethics; 2011; 39(2):296-300. PubMed ID: 21710799
    [No Abstract]   [Full Text] [Related]  

  • 6. Enabling policy planning and innovation management through patent information and co-authorship network analyses: a study of tuberculosis in Brazil.
    Vasconcellos AG; Morel CM
    PLoS One; 2012; 7(10):e45569. PubMed ID: 23056208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Special patent provisions for pharmaceuticals: have they outlived their usefulness? A political, legislative and legal history of U.S. law and observations for the future.
    Engelberg AB
    Spec Law Dig Health Care Law; 2000 Sep; (258):9-48. PubMed ID: 11184791
    [No Abstract]   [Full Text] [Related]  

  • 9. Using market-exclusivity incentives to promote pharmaceutical innovation.
    Kesselheim AS
    N Engl J Med; 2010 Nov; 363(19):1855-62. PubMed ID: 21047231
    [No Abstract]   [Full Text] [Related]  

  • 10. [History of Brazil's tobacco control policy from 1986 to 2016].
    Portes LH; Machado CV; Turci SRB
    Cad Saude Publica; 2018 Feb; 34(2):e00017317. PubMed ID: 29489940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Specificities of patent protection in the pharmaceutical industry: modalities and traits of intellectual property].
    Jannuzzi AH; Vasconcellos AG; de Souza CG
    Cad Saude Publica; 2008 Jun; 24(6):1205-18. PubMed ID: 18545747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
    Hemphill Kraus EJ
    N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical patent law: the Canadian perspective.
    Aumand L; Norman J
    Pharm Pat Anal; 2016 Jul; 5(4):271-9. PubMed ID: 27346187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expedited pharma patenting in Brazil.
    Moreira P
    Pharm Pat Anal; 2019 Mar; 8(2):51-59. PubMed ID: 30887881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosecurity's unruly spaces.
    Mather C; Marshall A
    Geogr J; 2011; 177(4):300-10. PubMed ID: 22180920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Learning about new products: an empirical study of physicians' behavior.
    Ferreyra MM; Kosenok G
    Econ Inq; 2011; 49(3):876-98. PubMed ID: 22022733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmaceutical patents and the accessibility of drugs in Brazil].
    Marques MB
    Hist Cienc Saude Manguinhos; 2000; 7(1):7-21. PubMed ID: 11625765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The consequences of 'double examination' for pharmaceutical patent applications in Brazil.
    Salerno G
    Pharm Pat Anal; 2017 Mar; 6(2):49-51. PubMed ID: 28274178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.